To the content
4 . 2022

Management of obesity: pharmacological approach

Abstract

Today, weight gain has a number of negative consequences, including a significant increase in the risk of diabetes mellitus. This article highlights the evidence on the effects of drug therapy with sibutramine, a neurotransmitter reuptake inhibitor, and its effects in combination with metformin in patients with obesity.

Keywords:obesity; diabetes mellitus; drug therapy; sibutramine

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Ametov A.S., Vovk P.S. Management of obesity: pharmacological approach. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (4): 89–94. DOI: https://doi.org/10.33029/2304-9529-2022-11-4-89-94 (in Russian)

References

1. World Health Organization. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

2. Ametov A.S. The Obesity. Modern view on pathogenesis and therapy: Textbook. Moscow: GEOTAR-Media, 2019; (1): 384 p. (in Russian)

3. Peterkova V.A., Bezlepkina O.B., Bolotova N.V., Bogova E.A., et al. Clinical guidelines “Obesity in children”. Problemi endocrinologii [Problems of Endocrinology]. 2021; 67 (5): 67–83. DOI: https://doi.org/10.14341/probl12802 (in Russian)

4. Tishkovskiy S.V., Nikonova L.V., Doroshkevich I.P. Modern approaches to treatment of obesity. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta [Journal of the Grodno State Medical University]. 2015: (2): 134–9. URL: https://cyberleninka.ru/article/n/sovremennye-podhody-k-lecheniyu-ozhireniya (in Russian)

5. Taganov A.V., Tikhomirov T.A., Rozhdestvenskaya O.A., Zaslavsky D.V., et al. Obesity as a factor contributing to pathogenesis of skin diseases. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (4): 52–61. DOI: https://doi.org/10.33029/2304-9529-2021-10-4-52-61 (in Russian)

6. Misharova A.P., Ametov A.S. Adipose tissue as a plastic organ to management obesity and diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (2): 64–70. DOI: https://doi.org/10.33029/2304-9529-2022-11-2-64-70 (in Russian)

7. Bray G.A., Heisel W.E., Afshin A., et al. The Science of Obesity Management: An Endocrine Society Scientific Statement // Endocr Rev. 2018; 39 (2): 79–132.

8. Zembic A., Eckel N., Stefan N., Baudry J., Schulze M.B. An empirically derived definition of metabolically healthy obesity based on risk of cardiovascular and total mortality. JAMA Netw Open. 2021; 4 (5):e218505. DOI: https://doi.org/10.1001/jamanetworkopen.2021.8505

9. Romantsova T.I., Ostrovskaya E.V. Metabolically healthy obesity: definitions, protective factors, and clinical significance. Al’manakh klinicheskoy meditsiny [Almanac of Clinical Medicine]. 2015; (1): 75–86. (in Russian)

10. Pyanykh O.P., Gusenbekova D.G., Ametov A.S. Advantages of long-term management the metabolic health in patients with obesity and early disorders of carbohydrate metabolism. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (2): 40–8. DOI: https://doi.org/10.33029/2304-9529-2020-9-2-40-48 (in Russian)

11. Ametov A.S., Pyanykh O.P., Nevolnikova A.O. Modern opportunities of metabolic health management in patients with obesity and carbohydrate metabolism disorders. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (1): 17–26. DOI: https://doi.org/10.33029/2304-9529-2020-9-1-17-26 (in Russian)

12. Sjöström L., Rissanen A., Andersen T., et al.; European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352 (9123): 167–72. DOI: https://doi.org/10.1016/s0140-6736(97)11509-4

13. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27 (1): 155–61. DOI: https://doi.org/10.2337/diacare.27.1.155

14. Antsiferov M.B., Markova T.N. State-of-the-art drug therapies of obesity. Doctor.Ru. 2021; 20 (2): 45–50. DOI: https://doi.org/10.31550/1727-2378-2021-20-2-45-50 (in Russian)

15. Chukhrova M.G. Eating disorders and psychological disorders in women with excessive body weight. Psychosomatic medicine: materials of the 1st International Congress, 8–9 June 2006, St. Petersburg. St. Petersburg: Medlay-Media Publ., 2006: 244 p. (in Russian)

16. Moncrieff J., Cooper R.E., Stockmann T., et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2022. DOI: https://doi.org/10.1038/s41380-022-01661-0

17. Leonova E.N. Socio-psychological types of eating behavior. Vestnik Udmurtskogo universiteta. Seriya “Filosofiya. Psikhologiya. Pedagogika” [Bulletin of Udmurt University. Series: Philosophy. Psychology. Pedagogy]. 2017; 27 (2): 174–81. (in Russian)

18. Salmina-Khvostova O.I. Eating disorder at obesity (epidemiological, clinicaldynamic, preventive, rehabilitation aspects): Abstract of Diss. Tomsk, 2008: 42 p. (in Russian)

19. Matveev G.А., Babenko A.Yu. Efficacy of sibutramine in different types of eating behavior in obese patients. Medical Council [Meditsinskiy Sovet]. 2022; 16 (10): 140–7. DOI: https://doi.org/10.21518/2079-701X-2022-16-10-140-147 (in Russian)

20. Matveev G.A., Golikova T.I., Vasileva A.A., Vasilieva E.V., et al. Comparison of the effects of liraglutide and sibutramine in obese patients. Ozhirenie i metabolism [Obesity and Metabolism]. 2021; 18 (2): 218–28. DOI: https://doi.org/10.14341/omet12498 (in Russian)

21. Galieva M.O., Ershova E.V., Komshilova K.A. Sibutramine: myths and realities. Ozhirenie i metabolism [Obesity and Metabolism]. 2014; 11 (4): 12–7. (in Russian)

22. Porter J.A., Raebel M.A., Conner D.A., et al. The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care. 2004; 10 (6): 369–76.

23. Hayes J.F., Bhaskaran K., Batterham R., Smeeth L., Douglas I. The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. Int J Obes (Lond). 2015; 39 (9): 1359–64. DOI: https://doi.org/10.1038/ijo.2015.86

24. Demidova T.Yu., Izmailova M.Ya., Ushakova S.E., Zaslavskaya K.Ya., et al. Evaluation of weight reduction efficacy and safety of sibutramin-containing drugs in patients with alimentary obesity. Farmatsiya i farmakologiya [Pharmacy & Pharmacology]. 2022; 10 (3): 289–304. DOI: https://doi.org/10.19163/2307-9266-2022-10-3-289-304 (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)
Вскрытие

Journals of «GEOTAR-Media»